TME Pharma N.V., (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today the amendment of the Articles of Association effecting the share consolidation such that every 100 shares with a nominal value of 1 eurocent each were consolidated and converted into 1 new share with a nominal value of 1 euro. With the publication of this press release, i.e., after the share consolidation has taken effect, the total issued share capital amounts to €1,361,094 divided into 1,361,094 shares of € 1.00 each. Trading of the new shares with ISIN NL0015000YE1 on the Euronext Growth Paris…